
Opinion|Videos|July 8, 2024
Emerging Pathways and Role of TROP2-Directed ADCs in HR+/HER2- mBC
Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD
Medical oncologists provide insights on emerging pathways and TROP2-directed antibody-drug conjugates in HR+/HER2- metastatic breast cancer, highlighting ongoing research.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- Please comment on emerging pathways and how they might impact the future treatment landscape for patients with HR+/HER2-negative metastatic breast cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
5


















